

Werner Poewe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9272488/publications.pdf>

Version: 2024-02-01

623
papers

71,283
citations

872

117
h-index

851

244
g-index

684
all docs

684
docs citations

684
times ranked

38646
citing authors

#	ARTICLE	IF	CITATIONS
1	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008, 23, 2129-2170.	3.9	4,796
2	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1591-1601.	3.9	4,389
3	Second consensus statement on the diagnosis of multiple system atrophy. <i>Neurology</i> , 2008, 71, 670-676.	1.1	2,720
4	A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease. <i>New England Journal of Medicine</i> , 2006, 355, 896-908.	27.0	2,577
5	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707.	3.9	2,497
6	Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations The Movement Disorder Society Task Force on rating scales for Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1020-1028.	3.9	1,739
7	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017, 32, 853-864.	3.9	1,402
8	Rivastigmine for Dementia Associated with Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2509-2518.	27.0	1,111
9	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007, 22, 41-47.	3.9	1,097
10	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1600-1611.	3.9	1,033
11	Pallidal Deep-Brain Stimulation in Primary Generalized or Segmental Dystonia. <i>New England Journal of Medicine</i> , 2006, 355, 1978-1990.	27.0	980
12	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007, 22, 2314-2324.	3.9	885
13	A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2009, 361, 1268-1278.	27.0	830
14	A Mutation in VPS35, Encoding a Subunit of the Retromer Complex, Causes Late-Onset Parkinson Disease. <i>American Journal of Human Genetics</i> , 2011, 89, 168-175.	6.2	757
15	Early consolidation in human primary motor cortex. <i>Nature</i> , 2002, 415, 640-644.	27.8	720
16	The diagnosis of Parkinson's disease. <i>Lancet Neurology</i> , The, 2006, 5, 75-86.	10.2	665
17	Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. <i>Movement Disorders</i> , 2019, 34, 180-198.	3.9	619
18	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017, 32, 1264-1310.	3.9	608

#	ARTICLE	IF	CITATIONS
19	Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. <i>Lancet, The</i> , 2005, 365, 947-954.	13.7	601
20	Depression rating scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2007, 22, 1077-1092.	3.9	583
21	Toll-like receptor 4 is required for α -synuclein dependent activation of microglia and astroglia. <i>Glia</i> , 2013, 61, 349-360.	4.9	542
22	Non-motor symptoms in Parkinson's disease. <i>European Journal of Neurology</i> , 2008, 15, 14-20.	3.3	524
23	Chronic Infections and the Risk of Carotid Atherosclerosis. <i>Circulation</i> , 2001, 103, 1064-1070.	1.6	491
24	Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). <i>Movement Disorders</i> , 2004, 19, 1391-1402.	3.9	481
25	Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2010, 9, 573-580.	10.2	476
26	Challenges in the diagnosis of Parkinson's disease. <i>Lancet Neurology, The</i> , 2021, 20, 385-397.	10.2	468
27	Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease. <i>Circulation</i> , 2004, 109, 2175-2180.	1.6	466
28	Prevalence and incidence of Parkinson's disease in Europe. <i>European Neuropsychopharmacology</i> , 2005, 15, 473-490.	0.7	461
29	<sc>EFNS</sc>/<sc>MDS</sc>'s recommendations for the diagnosis of <sc>P</sc>arkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 16-34.	3.3	460
30	Multiple system atrophy. <i>Lancet Neurology, The</i> , 2004, 3, 93-103.	10.2	443
31	The natural history of multiple system atrophy: a prospective European cohort study. <i>Lancet Neurology, The</i> , 2013, 12, 264-274.	10.2	426
32	The onset of nonmotor symptoms in Parkinson's disease (The ONSET PD Study). <i>Movement Disorders</i> , 2015, 30, 229-237.	3.9	402
33	Rotigotine effects on early morning motor function and sleep in Parkinson's disease: A double-blind, randomized, placebo-controlled study (RECOVER). <i>Movement Disorders</i> , 2011, 26, 90-99.	3.9	394
34	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 454-462.	3.9	379
35	Progression of Dysarthria and Dysphagia in Postmortem-Confirmed Parkinsonian Disorders. <i>Archives of Neurology</i> , 2001, 58, 259.	4.5	375
36	Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1064-1071.	3.9	374

#	ARTICLE	IF	CITATIONS
37	Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. <i>Lancet Neurology, The</i> , 2010, 9, 1070-1077.	10.2	349
38	Normative EMG Values during REM Sleep for the Diagnosis of REM Sleep Behavior Disorder. <i>Sleep</i> , 2012, 35, 835-847.	1.1	332
39	Levodopa in the treatment of Parkinson's disease: Current controversies. <i>Movement Disorders</i> , 2004, 19, 997-1005.	3.9	331
40	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDEâ€”PD study. <i>Annals of Neurology</i> , 2010, 68, 18-27.	5.3	330
41	The Parkinson's progression markers initiative (PPMI) â€” establishing a PD biomarker cohort. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1460-1477.	3.7	330
42	Pallidal deep brain stimulation in patients with primary generalised or segmental dystonia: 5-year follow-up of a randomised trial. <i>Lancet Neurology, The</i> , 2012, 11, 1029-1038.	10.2	329
43	Body Iron Stores and the Risk of Carotid Atherosclerosis. <i>Circulation</i> , 1997, 96, 3300-3307.	1.6	316
44	Summary of the recommendations of the <sc>EFNS</sc>/<sc>MDS</sc>â€”<sc>ES</sc> review on therapeutic management of <sc>P</sc>arkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 5-15.	3.3	290
45	Seminar on choreas. <i>Lancet Neurology, The</i> , 2006, 5, 589-602.	10.2	282
46	Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. <i>Lancet Neurology, The</i> , 2014, 13, 875-884.	10.2	281
47	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three Doses of Botulinum Toxin Type A (Dysport) With Placebo in Upper Limb Spasticity After Stroke. <i>Stroke</i> , 2000, 31, 2402-2406.	2.0	280
48	Prevalence of movement disorders in men and women aged 50â€”89 years (Bruneck Study cohort): a population-based study. <i>Lancet Neurology, The</i> , 2005, 4, 815-820.	10.2	271
49	Treatment interventions for Parkinson's disease: an evidence based assessment. <i>Lancet, The</i> , 2002, 359, 1589-1598.	13.7	266
50	Parkinson disease and the immune system â€” associations, mechanisms and therapeutics. <i>Nature Reviews Neurology</i> , 2020, 16, 303-318.	10.1	254
51	Minimal clinically important change on the unified Parkinson's disease rating scale. <i>Movement Disorders</i> , 2006, 21, 1200-1207.	3.9	253
52	PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. <i>Nature Genetics</i> , 2008, 40, 946-948.	21.4	252
53	Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2002, 109, 329-339.	2.8	250
54	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. <i>Lancet Neurology, The</i> , 2017, 16, 701-711.	10.2	248

#	ARTICLE	IF	CITATIONS
55	Neurological Outcome of Septic Cardioembolic Stroke After Infective Endocarditis. <i>Stroke</i> , 2006, 37, 2094-2099.	2.0	234
56	Health-related quality of life scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2011, 26, 2371-2380.	3.9	234
57	Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. <i>Lancet Neurology</i> , The, 2007, 6, 826-829.	10.2	231
58	Toll-Like Receptor 4 Promotes α -Synuclein Clearance and Survival of Nigral Dopaminergic Neurons. <i>American Journal of Pathology</i> , 2011, 179, 954-963.	3.8	230
59	The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy. <i>Movement Disorders</i> , 2022, 37, 1131-1148.	3.9	222
60	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007, 22, 2409-2417.	3.9	221
61	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2016, 15, 154-165.	10.2	219
62	Modafinil for the Treatment of Daytime Sleepiness in Parkinson's Disease: A Double-blind, Randomized, Crossover, Placebo-controlled Polygraphic Trial. <i>Sleep</i> , 2002, 25, 62-66.	1.1	216
63	Red flags for multiple system atrophy. <i>Movement Disorders</i> , 2008, 23, 1093-1099.	3.9	215
64	Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 2704-2716.	3.9	214
65	Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry. <i>Movement Disorders</i> , 2010, 25, 2604-2612.	3.9	205
66	White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion tensor imaging and voxel-based morphometry study. <i>Annals of Neurology</i> , 2011, 69, 400-407.	5.3	203
67	Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2018, 17, 749-759.	10.2	203
68	Premotor signs and symptoms of multiple system atrophy. <i>Lancet Neurology</i> , The, 2012, 11, 361-368.	10.2	201
69	Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 873-878.	3.9	200
70	Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2008, 7, 595-604.	10.2	195
71	The Concept of Prodromal Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 681-697.	2.8	195
72	Levodopa in the treatment of Parkinson's disease: an old drug still going strong. <i>Clinical Interventions in Aging</i> , 2010, 5, 229.	2.9	194

#	ARTICLE	IF	CITATIONS
73	Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 805-822.	3.9	193
74	Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group. <i>Movement Disorders</i> , 2014, 29, 857-867.	3.9	193
75	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology</i> , The, 2011, 10, 415-423.	10.2	192
76	Oxidative Stress in Transgenic Mice with Oligodendroglial α -Synuclein Overexpression Replicates the Characteristic Neuropathology of Multiple System Atrophy. <i>American Journal of Pathology</i> , 2005, 166, 869-876.	3.8	191
77	Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: a meta-analysis. <i>Lancet Neurology</i> , The, 2017, 16, 898-907.	10.2	191
78	Influence of Concurrent Tasks on Gait: A Dual-Task Approach. <i>Perceptual and Motor Skills</i> , 1995, 81, 107-113.	1.3	190
79	Management of Spasticity Associated Pain with Botulinum Toxin A. <i>Journal of Pain and Symptom Management</i> , 2000, 20, 44-49.	1.2	184
80	Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Societyâ€™European Section (MDSâ€™ES). Part II: late (complicated) Parkinson's disease. <i>European Journal of Neurology</i> , 2006, 13, 1186-1202.	3.3	183
81	The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. <i>Journal of Neurology</i> , 2002, 249, 842-846.	3.6	180
82	Therapies in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2012, 25, 433-447.	3.6	180
83	Clinical and polymyographic investigation of spasmodic torticollis. <i>Journal of Neurology</i> , 1992, 239, 9-15.	3.6	175
84	Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. <i>Lancet Neurology</i> , The, 2013, 12, 747-755.	10.2	175
85	Neuropathological criteria of anti-IgG5-related tauopathy. <i>Acta Neuropathologica</i> , 2016, 132, 531-543.	7.7	173
86	Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 216.	9.0	171
87	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1601-1608.	3.9	171
88	Levodopa in the treatment of Parkinson's disease. <i>European Journal of Neurology</i> , 2009, 16, 982-989.	3.3	163
89	Minocycline 1-year therapy in multiple system atrophy: Effect on clinical symptoms and [¹¹ C]-(R)-PK11195 PET (MEMSA-trial). <i>Movement Disorders</i> , 2010, 25, 97-107.	3.9	163
90	Genome-Wide Association Study Identifies Novel Restless Legs Syndrome Susceptibility Loci on 2p14 and 16q12.1. <i>PLoS Genetics</i> , 2011, 7, e1002171.	3.5	163

#	ARTICLE	IF	CITATIONS
91	Milestones in Parkinson's disease therapeutics. <i>Movement Disorders</i> , 2011, 26, 1072-1082.	3.9	162
92	Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2017, 82, 419-428.	5.3	161
93	Quantification of Electromyographic Activity During REM Sleep in Multiple Muscles in REM Sleep Behavior Disorder. <i>Sleep</i> , 2008, 31, 724-731.	1.1	160
94	Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 1357-1363.	3.9	159
95	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1133-1144.	2.2	156
96	Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2003, 18, 1132-1138.	3.9	153
97	Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain. <i>Journal of Neurology</i> , 2006, 253, 1337-1341.	3.6	153
98	Prevalence and Burden of Gait Disorders in Elderly Men and Women Aged 60-97 Years: A Population-Based Study. <i>PLoS ONE</i> , 2013, 8, e69627.	2.5	151
99	Ischemic stress induces deposition of amyloid β immunoreactivity in human brain. <i>Acta Neuropathologica</i> , 1995, 90, 461-466.	7.7	149
100	Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. <i>NeuroImage</i> , 2004, 21, 1443-1451.	4.2	149
101	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 13-20.	2.2	149
102	Enlarged Substantia Nigra Hyperechogenicity and Risk for Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 932.	4.5	146
103	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 197.	9.0	146
104	Temporal Profile and Cell Subtype Distribution of Activated Caspase-3 Following Experimental Traumatic Brain Injury. <i>Journal of Neurochemistry</i> , 2000, 75, 1264-1273.	3.9	142
105	Brain perfusion scintigraphy with ^{99m}Tc -HMPAO or ^{99m}Tc -ECD and ^{123}I - ^{125}I -CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 24, 320-325.	2.1	137
106	Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized Dystonia. <i>American Journal of Human Genetics</i> , 2016, 99, 1377-1387.	6.2	135
107	Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. <i>Lancet Neurology</i> , The, 2011, 10, 710-720.	10.2	133
108	Pallidal deep brain stimulation improves quality of life in segmental and generalized dystonia: Results from a prospective, randomized sham-controlled trial. <i>Movement Disorders</i> , 2008, 23, 131-134.	3.9	131

#	ARTICLE	IF	CITATIONS
109	Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 619-623.	3.9	129
110	Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. <i>Journal of Neurology</i> , 2013, 260, 2701-2714.	3.6	128
111	Apomorphine: An underutilized therapy for Parkinson's disease. <i>Movement Disorders</i> , 2000, 15, 789-794.	3.9	127
112	Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG). <i>Movement Disorders</i> , 2006, 21, 179-186.	3.9	126
113	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology</i> , 2013, 12, 514-524.	10.2	126
114	Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease – Clinical practice recommendations. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1023-1030.	2.2	126
115	Impaired dopaminergic neurotransmission in patients with traumatic brain injury: a SPET study using ¹²³ I-β-CIT and ¹²³ I-IBZM. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1410-1414.	2.1	125
116	Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism. <i>Movement Disorders</i> , 2015, 30, 1068-1076.	3.9	125
117	Botulinum Toxin A in the Management of Spastic Gait Disorders in Children and Young Adults with Cerebral Palsy: A Randomized, Double-Blind Study of "High-Dose" versus "Low-Dose" Treatment*. <i>Neuropediatrics</i> , 1999, 30, 120-124.	0.6	122
118	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013, 28, 1838-1846.	3.9	122
119	Video analysis of motor events in REM sleep behavior disorder. <i>Movement Disorders</i> , 2007, 22, 1464-1470.	3.9	121
120	Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2015, 85, 1761-1768.	1.1	121
121	Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. <i>Brain</i> , 2006, 129, 538-542.	7.6	120
122	Expression of Fas and Fas Ligand After Experimental Traumatic Brain Injury in the Rat. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2000, 20, 669-677.	4.3	118
123	Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 231-235.	2.2	118
124	Brain stem pathology in Parkinson's disease: An evaluation of the Braak staging model. <i>Movement Disorders</i> , 2010, 25, 2508-2515.	3.9	117
125	Voxel-wise analysis of [¹²³ I]β-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. <i>Brain</i> , 2005, 128, 1605-1612.	7.6	115
126	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1643-1646.	3.9	114

#	ARTICLE	IF	CITATIONS
127	Defining atâ€risk populations for Parkinson's disease: Lessons from ongoing studies. <i>Movement Disorders</i> , 2012, 27, 656-665.	3.9	113
128	The <scp>PRIPS</scp> study: screening battery for subjects at risk for <scp>P</scp>arkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 102-108.	3.3	113
129	Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 216-219.	3.9	112
130	Regional differences in the severity of Lewy body pathology across the olfactory cortex. <i>Neuroscience Letters</i> , 2009, 453, 77-80.	2.1	110
131	Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. <i>Parkinsonism and Related Disorders</i> , 2017, 40, 1-10.	2.2	110
132	Longâ€term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study. <i>Movement Disorders</i> , 2006, 21, 456-461.	3.9	109
133	Progression of brain atrophy in multiple system atrophy. <i>Journal of Neurology</i> , 2007, 254, 191-196.	3.6	108
134	Probabilistic mapping of the antidystonic effect of pallidal neurostimulation: a multicentre imaging study. <i>Brain</i> , 2019, 142, 1386-1398.	7.6	105
135	Treatment of spasmodic torticollis with local injections of botulinum toxin. <i>Journal of Neurology</i> , 1992, 239, 21-25.	3.6	103
136	Kava and dopamine antagonism.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1995, 58, 639-640.	1.9	102
137	Healthâ€related quality of life in multiple system atrophy. <i>Movement Disorders</i> , 2006, 21, 809-815.	3.9	102
138	Wearingâ€off scales in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2011, 26, 2169-2175.	3.9	101
139	Progression of putaminal degeneration in multiple system atrophy: A serial diffusion MR study. <i>NeuroImage</i> , 2006, 31, 240-245.	4.2	98
140	Active and Passive Smoking, Chronic Infections, and the Risk of Carotid Atherosclerosis. <i>Stroke</i> , 2002, 33, 2170-2176.	2.0	97
141	Extended-release pramipexole in advanced Parkinson disease. <i>Neurology</i> , 2011, 77, 767-774.	1.1	97
142	Clinical characteristics of the geste antagoniste in cervical dystonia. <i>Journal of Neurology</i> , 2001, 248, 478-482.	3.6	96
143	The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: Association with ferritin levels. <i>Sleep Medicine</i> , 2009, 10, 611-615.	1.6	96
144	Myeloperoxidase Inhibition Ameliorates Multiple System Atrophy-Like Degeneration in a Transgenic Mouse Model. <i>Neurotoxicity Research</i> , 2012, 21, 393-404.	2.7	96

#	ARTICLE	IF	CITATIONS
145	Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease. <i>Brain</i> , 2012, 135, 3348-3354.	7.6	95
146	Mortality in Parkinson's disease: A 38-year follow-up study. <i>Movement Disorders</i> , 2015, 30, 266-269.	3.9	95
147	Clinical exome sequencing in early-onset generalized dystonia and large-scale resequencing follow-up. <i>Movement Disorders</i> , 2017, 32, 549-559.	3.9	94
148	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019, 34, 1228-1232.	3.9	93
149	Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. <i>CNS Drugs</i> , 2019, 33, 905-918.	5.9	92
150	Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. <i>Brain</i> , 2021, 144, 1118-1126.	7.6	92
151	Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2009, 24, 1906-1909.	3.9	91
152	Usefulness of the SINBAR electromyographic montage to detect the motor and vocal manifestations occurring in REM sleep behavior disorder. <i>Sleep Medicine</i> , 2011, 12, 284-288.	1.6	91
153	Low concentrations of STI571 in the cerebrospinal fluid: a case report. <i>British Journal of Haematology</i> , 2002, 117, 623-625.	2.5	90
154	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 1131-1142.	3.9	90
155	Delayed Diagnosis, Range of Severity, and Multiple Sleep Comorbidities: A Clinical and Polysomnographic Analysis of 100 Patients of the Innsbruck Narcolepsy Cohort. <i>Journal of Clinical Sleep Medicine</i> , 2013, 09, 805-812.	2.6	90
156	Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2015, 14, 145-152.	10.2	90
157	Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. <i>Annals of Neurology</i> , 2016, 79, 1026-1030.	5.3	90
158	Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint. <i>Movement Disorders</i> , 1999, 14, 911-913.	3.9	89
159	Neurological effects of recombinant human erythropoietin in Friedreich's ataxia: A clinical pilot trial. <i>Movement Disorders</i> , 2008, 23, 1940-1944.	3.9	89
160	Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism. <i>Neurology</i> , 2016, 86, 1242-1249.	1.1	89
161	Motor and nonmotor complications of levodopa: Phenomenology, Risk Factors, and Imaging Features. <i>Movement Disorders</i> , 2018, 33, 909-919.	3.9	89
162	Glial cell death induced by overexpression of α -synuclein. <i>Journal of Neuroscience Research</i> , 2001, 65, 432-438.	2.9	87

#	ARTICLE	IF	CITATIONS
163	Atrophy pattern in SCA2 determined by voxel-based morphometry. <i>NeuroReport</i> , 2003, 14, 1799-1802.	1.2	87
164	Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2542-2549.	3.9	87
165	Validation of the Innsbruck REM sleep behavior disorder inventory. <i>Movement Disorders</i> , 2012, 27, 1673-1678.	3.9	87
166	Supine hypertension in Parkinson's disease and multiple system atrophy. <i>Clinical Autonomic Research</i> , 2016, 26, 97-105.	2.5	87
167	Comparison of diffusion-weighted imaging and [¹²³ I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 1438-1445.	3.9	86
168	Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: A randomized, placebo-controlled polysomnographic study. <i>Sleep Medicine</i> , 2010, 11, 848-856.	1.6	86
169	Probable RBD and association with neurodegenerative disease markers: A population-based study. <i>Movement Disorders</i> , 2015, 30, 1417-1421.	3.9	86
170	Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. <i>Sleep Medicine</i> , 2015, 16, 186-189.	1.6	86
171	Costs of illness and care in Parkinson's Disease: An evaluation in six countries. <i>European Neuropsychopharmacology</i> , 2011, 21, 180-191.	0.7	84
172	Excessive Daytime Sleepiness in Multiple System Atrophy (SLEEMSA Study). <i>Archives of Neurology</i> , 2011, 68, 223-30.	4.5	83
173	Extended-release pramipexole in early Parkinson disease. <i>Neurology</i> , 2011, 77, 759-766.	1.1	83
174	Safety and immunogenicity of the α -synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial. <i>Lancet Neurology</i> , The, 2020, 19, 591-600.	10.2	83
175	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology</i> , The, 2016, 15, 546-548.	10.2	82
176	Efficacy and safety of a standardised 500 unit dose of Dysport \AA (Clostridium botulinum toxin type A) Tj ETQq0 0 0 rgBT /Overlock 10 multicentre, randomised, double-blind, placebo-controlled, parallel group study. <i>Journal of Neurology</i> , 2001, 248, 1073-1078.	3.6	79
177	Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2019, 18, 724-735.	10.2	79
178	Replication of restless legs syndrome loci in three European populations. <i>Journal of Medical Genetics</i> , 2009, 46, 315-318.	3.2	78
179	Genome-wide association study in essential tremor identifies three new loci. <i>Brain</i> , 2016, 139, 3163-3169.	7.6	78
180	Animal models of multiple system atrophy. <i>Trends in Neurosciences</i> , 2005, 28, 501-506.	8.6	77

#	ARTICLE	IF	CITATIONS
181	Diagnosis and management of Parkinson's disease dementia. <i>International Journal of Clinical Practice</i> , 2008, 62, 1581-1587.	1.7	77
182	Clinical measures of progression in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, S671-6.	3.9	77
183	Prevalence of Primary Headaches and Cranial Neuralgias in Men and Women Aged 55-94 Years (Bruneck). <i>Tijdschrift voor Neurologie</i> , 2011, 11, 1078-1084.	3.9	77
184	Parkinsonism in multiple system atrophy: Natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease. <i>Movement Disorders</i> , 2002, 17, 701-709.	3.9	76
185	Voxel-based morphometry in narcolepsy. <i>Sleep Medicine</i> , 2005, 6, 531-536.	1.6	76
186	Which dyskinesia scale best detects treatment response?. <i>Movement Disorders</i> , 2013, 28, 341-346.	3.9	76
187	Novel formulations and modes of delivery of levodopa. <i>Movement Disorders</i> , 2015, 30, 114-120.	3.9	76
188	The European Multiple System Atrophy-Study Group (EMSA-SG). <i>Journal of Neural Transmission</i> , 2005, 112, 1677-1686.	2.8	75
189	REM sleep behavior disorder in 703 sleep-disorder patients: The importance of eliciting a comprehensive sleep history. <i>Sleep Medicine</i> , 2010, 11, 167-171.	1.6	75
190	A cross-sectional multicenter study of cognitive and behavioural features in multiple system atrophy patients of the parkinsonian and cerebellar type. <i>Journal of Neural Transmission</i> , 2013, 120, 613-618.	2.8	75
191	Long-Term Follow-up Investigation of Isolated Rapid Eye Movement Sleep Without Atonia Without Rapid Eye Movement Sleep Behavior Disorder: A Pilot Study. <i>Journal of Clinical Sleep Medicine</i> , 2015, 11, 1273-1279.	2.6	75
192	Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. <i>Journal of Neurology</i> , 2002, 249, 300-304.	3.6	74
193	Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain-pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy. <i>Movement Disorders</i> , 2010, 25, 2444-2449.	3.9	74
194	Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. <i>Journal of Hepatology</i> , 2010, 53, 1101-1107.	3.7	74
195	Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. <i>Sleep Medicine</i> , 2011, 12, 351-360.	1.6	74
196	Five-year follow-up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder. <i>Movement Disorders</i> , 2014, 29, 1774-1780.	3.9	74
197	Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human α -synuclein under oligodendrocyte promoter: implications for multiple system atrophy. <i>Acta Neuropathologica</i> , 2012, 124, 51-65.	7.7	73
198	Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. <i>Movement Disorders</i> , 2018, 33, 1528-1539.	3.9	73

#	ARTICLE	IF	CITATIONS
199	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
200	Riluzole in Huntington's disease (HD): an open label study with one year follow up. <i>Journal of Neurology</i> , 2001, 248, 866-869.	3.6	71
201	Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community. <i>Movement Disorders</i> , 2016, 31, 1405-1408.	3.9	71
202	Increased daytime sleepiness in Parkinson's disease: A questionnaire survey. <i>Movement Disorders</i> , 2003, 18, 319-323.	3.9	70
203	Number processing and basal ganglia dysfunction: a single case study. <i>Neuropsychologia</i> , 2004, 42, 1050-1062.	1.6	70
204	Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 284-288.	3.9	68
205	Cortical atrophy in the cerebellar variant of multiple system atrophy: A voxel-based morphometry study. <i>Movement Disorders</i> , 2006, 21, 159-165.	3.9	67
206	Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 36-41.	2.2	67
207	Amantadine in the treatment of Parkinson's disease and other movement disorders. <i>Lancet Neurology</i> , The, 2021, 20, 1048-1056.	10.2	67
208	Safety and tolerability of growth hormone therapy in multiple system atrophy: A double-blind, placebo-controlled study. <i>Movement Disorders</i> , 2007, 22, 1138-1144.	3.9	66
209	Management of Motor and Non-Motor Symptoms in Parkinson's Disease. <i>CNS Drugs</i> , 2013, 27, 259-272.	5.9	66
210	Increased Expression of Apolipoprotein D Following Experimental Traumatic Brain Injury. <i>Journal of Neurochemistry</i> , 2002, 73, 1615-1625.	3.9	65
211	Orthostatic hypotension and attention in Parkinson's disease with and without dementia. <i>Journal of Neural Transmission</i> , 2007, 114, 585-588.	2.8	65
212	Decision making under risk and under ambiguity in Parkinson's disease. <i>Neuropsychologia</i> , 2009, 47, 1901-1908.	1.6	65
213	Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 536-544.	1.5	65
214	Perspectives on recent advances in the understanding and treatment of Parkinson's disease. <i>European Journal of Neurology</i> , 2009, 16, 1090-1099.	3.3	64
215	Periodic leg movements during sleep and periodic limb movement disorder in patients presenting with unexplained insomnia. <i>Clinical Neurophysiology</i> , 2009, 120, 257-263.	1.5	64
216	Investigation of autonomic function in idiopathic REM sleep behavior disorder. <i>Journal of Neurology</i> , 2012, 259, 1056-1061.	3.6	64

#	ARTICLE	IF	CITATIONS
217	The reorganization of functional architecture in the early-stages of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 61-68.	2.2	64
218	Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study. <i>Movement Disorders</i> , 2010, 25, 896-905.	3.9	63
219	Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson's Disease: A Cross-Sectional Study. <i>Gerontology</i> , 2019, 65, 216-228.	2.8	63
220	Topography of putaminal degeneration in multiple system atrophy: A diffusion magnetic resonance study. <i>Movement Disorders</i> , 2006, 21, 847-852.	3.9	62
221	Long-term Safety of Rivastigmine in Parkinson Disease Dementia. <i>Clinical Neuropharmacology</i> , 2014, 37, 9-16.	0.7	62
222	Medial temporal lobe activation during semantic language processing: fMRI findings in healthy left- and right-handers. <i>Cognitive Brain Research</i> , 2003, 17, 339-346.	3.0	61
223	Validation of an Integrated Software for the Detection of Rapid Eye Movement Sleep Behavior Disorder. <i>Sleep</i> , 2014, 37, 1663-1671.	1.1	61
224	Poor Response to Activated Protein C as a Prominent Risk Predictor of Advanced Atherosclerosis and Arterial Disease. <i>Circulation</i> , 1999, 99, 614-619.	1.6	60
225	Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. <i>European Heart Journal</i> , 2005, 26, 279-287.	2.2	60
226	Disturbance of rapid eye movement sleep in spinocerebellar ataxia type 2. <i>Movement Disorders</i> , 2006, 21, 1751-1754.	3.9	60
227	Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study. <i>Movement Disorders</i> , 2017, 32, 1457-1464.	3.9	60
228	Temporal and spatial profile of caspase 8 expression and proteolysis after experimental traumatic brain injury. <i>Journal of Neurochemistry</i> , 2001, 78, 862-873.	3.9	59
229	Topography of Dopamine Transporter Availability in Progressive Supranuclear Palsy. <i>Archives of Neurology</i> , 2006, 63, 1154.	4.5	59
230	Effect and safety of duodenal levodopa infusion in advanced Parkinson's disease: a retrospective multicenter outcome assessment in patient routine care. <i>Journal of Neural Transmission</i> , 2013, 120, 1553-1558.	2.8	59
231	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 86-95.	3.9	59
232	Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. <i>Journal of Neural Transmission</i> , 2003, 110, 611-626.	2.8	56
233	Cerebral vasoreactivity decreases overnight in severe obstructive sleep apnea syndrome: A study of cerebral hemodynamics. <i>Sleep Medicine</i> , 2009, 10, 875-881.	1.6	56
234	Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Neuroscience</i> , 2000, 99, 43-54.	2.3	55

#	ARTICLE	IF	CITATIONS
235	Progression of parkinsonism in multiple system atrophy. <i>Journal of Neurology</i> , 2005, 252, 91-96.	3.6	55
236	Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. <i>Journal of Neural Transmission</i> , 2013, 120, 1069-1081.	2.8	55
237	Mavoglurant in Parkinson's patients with Dopa-induced dyskinesias: Two randomized phase 2 studies. <i>Movement Disorders</i> , 2016, 31, 1054-1058.	3.9	55
238	Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1408-1413.	3.9	55
239	Non-Motor Symptoms in Parkinson's Disease are Reduced by Nabilone. <i>Annals of Neurology</i> , 2020, 88, 712-722.	5.3	55
240	How to diagnose MSA early: the role of magnetic resonance imaging. <i>Journal of Neural Transmission</i> , 2005, 112, 1625-1634.	2.8	54
241	Elastin Polymorphism Haplotype and Intracranial Aneurysms Are Not Associated in Central Europe. <i>Stroke</i> , 2003, 34, 1207-1211.	2.0	53
242	Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study. <i>Journal of Neurology</i> , 2010, 257, 638-645.	3.6	53
243	Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study. <i>Lancet Neurology</i> , The, 2015, 14, 48-56.	10.2	53
244	Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population-based 10-year study. <i>Movement Disorders</i> , 2018, 33, 405-413.	3.9	53
245	A Phase 1 Randomized Trial of Specific Active α -Synuclein Immunotherapies (PD01A and PD03A) in Multiple System Atrophy. <i>Movement Disorders</i> , 2020, 35, 1957-1965.	3.9	53
246	The Movement Disorders task force review of dysautonomia rating scales in Parkinson's disease with regard to symptoms of orthostatic hypotension. <i>Movement Disorders</i> , 2011, 26, 1985-1992.	3.9	52
247	Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. <i>Brain</i> , 2013, 136, 3028-3037.	7.6	52
248	Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. <i>Movement Disorders</i> , 2015, 30, 1885-1892.	3.9	52
249	Neuropathological and behavioral changes induced by various treatment paradigms with MPTP and 3-nitropropionic acid in mice: towards a model of striatonigral degeneration (multiple system) Tj ETQq1 1 0.784314.rgBT / Overlock 10 T		
250	Emerging therapies for Parkinson's disease. <i>Current Opinion in Neurology</i> , 2012, 25, 448-459.	3.6	51
251	Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release. <i>Parkinson's Disease</i> , 2014, 2014, 1-8.	1.1	51
252	Juvenile asymmetric segmental spinal muscular atrophy (Hirayama's disease) Three cases without evidence of œflexion myelopathy. <i>Acta Neurologica Scandinavica</i> , 2001, 104, 320-322.	2.1	50

#	ARTICLE	IF	CITATIONS
253	Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies. <i>Acta Neuropathologica Communications</i> , 2018, 6, 2.	5.2	50
254	Evaluation of Striatal Dopamine Transporter Function in Rats by in Vivo ^{123}I -[123I]CIT Pinhole SPECT. <i>NeuroImage</i> , 2002, 17, 128-141.	4.2	49
255	Transient and permanent magnetic resonance imaging abnormalities after complex partial status epilepticus. <i>Epilepsy and Behavior</i> , 2006, 8, 666-671.	1.7	49
256	Episodic ataxia type 2: phenotype characteristics of a novel CACNA1A mutation and review of the literature. <i>Journal of Neurology</i> , 2014, 261, 983-991.	3.6	49
257	IgLON5 autoimmunity and abnormal behaviours during sleep. <i>Lancet, The</i> , 2015, 385, 1590.	13.7	49
258	The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018, 54, 90-94.	2.2	49
259	^{123}I -CIT and ^{123}I -IBZM-SPECT scanning in levodopa-naive Parkinson's disease. <i>Movement Disorders</i> , 1998, 13, 438-445.	3.9	48
260	When a Parkinson's disease patient starts to hallucinate. <i>Practical Neurology</i> , 2008, 8, 238-241.	1.1	48
261	Teaching program for the movement disorder society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS). <i>Movement Disorders</i> , 2010, 25, 1190-1194.	3.9	48
262	Detecting nocturnal hypertension in Parkinson's disease and multiple system atrophy: proposal of a decision-support algorithm. <i>Journal of Neurology</i> , 2014, 261, 1291-1299.	3.6	47
263	Levodopa: 50 years of a revolutionary drug for Parkinson disease. <i>Movement Disorders</i> , 2015, 30, 1-3.	3.9	47
264	Magnetic resonance imaging and angiography in hemifacial spasm. <i>Neuroradiology</i> , 1992, 34, 413-416.	2.2	46
265	Quantification of sensory trick impact on tremor amplitude and frequency in 60 patients with head tremor. <i>Movement Disorders</i> , 2000, 15, 960-964.	3.9	46
266	The relation between abnormal behaviors and REM sleep microstructure in patients with REM sleep behavior disorder. <i>Sleep Medicine</i> , 2009, 10, 174-181.	1.6	46
267	White and Gray Matter Abnormalities in Narcolepsy with Cataplexy. <i>Sleep</i> , 2012, 35, 345-351.	1.1	46
268	Can observers link dream content to behaviours in rapid eye movement sleep behaviour disorder? A cross-sectional experimental pilot study. <i>Journal of Sleep Research</i> , 2012, 21, 21-29.	3.2	46
269	Brain structural profile of multiple system atrophy patients with cognitive impairment. <i>Journal of Neural Transmission</i> , 2017, 124, 293-302.	2.8	46
270	Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. <i>Parkinsonism and Related Disorders</i> , 2018, 52, 83-89.	2.2	46

#	ARTICLE	IF	CITATIONS
271	PLM detection by actigraphy compared to polysomnography: A validation and comparison of two actigraphs. <i>Sleep Medicine</i> , 2009, 10, 306-311.	1.6	45
272	Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. <i>Movement Disorders</i> , 2010, 25, 1464-1469.	3.9	45
273	MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. <i>Parkinsonism and Related Disorders</i> , 2018, 46, 47-55.	2.2	45
274	Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort. <i>Journal of Neural Transmission</i> , 2004, 111, 1473-1483.	2.8	44
275	Effects of Rivastigmine on Tremor and Other Motor Symptoms in Patients with Parkinson's Disease Dementia. <i>Drug Safety</i> , 2008, 31, 79-94.	3.2	44
276	Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0189897.	2.5	44
277	Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. <i>Journal of Nuclear Medicine</i> , 1998, 39, 954-60.	5.0	44
278	Parkinson's disease and sleep. <i>Current Opinion in Neurology</i> , 2000, 13, 423-426.	3.6	43
279	Decision Making and Executive Functions in REM Sleep Behavior Disorder. <i>Sleep</i> , 2012, 35, 667-673.	1.1	43
280	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016, 31, 1623-1627.	3.9	43
281	Sensor-based gait analysis in atypical parkinsonian disorders. <i>Brain and Behavior</i> , 2018, 8, e00977.	2.2	43
282	Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2010, 117, 1395-1399.	2.8	42
283	VPS35 Parkinson's disease phenotype resembles the sporadic disease. <i>Journal of Neural Transmission</i> , 2014, 121, 755-759.	2.8	42
284	Safety of prolonged sacral neuromodulation tined lead testing. <i>Current Medical Research and Opinion</i> , 2008, 24, 343-347.	1.9	41
285	Mortality in Parkinson's disease, a 20-year follow-up study. <i>Movement Disorders</i> , 2010, 25, 661-662.	3.9	41
286	Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. <i>European Journal of Neurology</i> , 2019, 26, 953-960.	3.3	41
287	Klüver-Bucy syndrome in man: Experiences with posttraumatic cases. <i>Neuroscience and Biobehavioral Reviews</i> , 1983, 7, 413-417.	6.1	40
288	Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies. <i>NeuroReport</i> , 2004, 15, 1711-1714.	1.2	40

#	ARTICLE	IF	CITATIONS
289	Alpha-synuclein immunoreactivity patterns in the enteric nervous system. <i>Neuroscience Letters</i> , 2015, 602, 145-149.	2.1	40
290	Association of Daytime Sleepiness with COMT Polymorphism in Patients with Parkinson Disease: a Pilot Study. <i>Sleep</i> , 2004, 27, 733-736.	1.1	39
291	Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study. <i>Parkinsonism and Related Disorders</i> , 2021, 83, 79-85.	2.2	39
292	Dystonia in ataxia telangiectasia: Report of a case with putaminal lesions and decreased striatal [^{123I}]iodobenzamide Binding. <i>Movement Disorders</i> , 1994, 9, 455-459.	3.9	38
293	Rationale for delayed-start study of pramipexole in Parkinson's disease: The PROUD study. <i>Movement Disorders</i> , 2010, 25, 1627-1632.	3.9	38
294	Risk factors and prodromal markers and the development of Parkinson's disease. <i>Journal of Neurology</i> , 2014, 261, 180-187.	3.6	38
295	Failure of Neuroprotection Despite Microglial Suppression by Delayed-Start Myeloperoxidase Inhibition in a Model of Advanced Multiple System Atrophy: Clinical Implications. <i>Neurotoxicity Research</i> , 2015, 28, 185-194.	2.7	38
296	Screening for idiopathic REM sleep behavior disorder: usefulness of actigraphy. <i>Sleep</i> , 2018, 41, .	1.1	38
297	Towards Neurotransplantation in Multiple System Atrophy: Clinical Rationale, Pathophysiological Basis, and Preliminary Experimental Evidence. <i>Cell Transplantation</i> , 2000, 9, 279-288.	2.5	37
298	Tumor necrosis factor- α -induced cell death in U373 cells overexpressing α -synuclein. <i>Journal of Neuroscience Research</i> , 2003, 73, 334-340.	2.9	37
299	Computerized Tremor Analysis of Valproate-induced Tremor: A Comparative Study of Controlled-release versus Conventional Valproate. <i>Epilepsia</i> , 2005, 46, 320-323.	5.1	37
300	Treatment of dementia with Lewy bodies and Parkinson's disease dementia. <i>Movement Disorders</i> , 2005, 20, S77-S82.	3.9	37
301	Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. <i>European Journal of Neurology</i> , 2007, 14, 66-72.	3.3	37
302	Skeletal Muscle Involvement in Friedreich Ataxia and Potential Effects of Recombinant Human Erythropoietin Administration on Muscle Regeneration and Neovascularization. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 708-715.	1.7	37
303	Molecular diversity of combined and complex dystonia: insights from diagnostic exome sequencing. <i>Neurogenetics</i> , 2017, 18, 195-205.	1.4	37
304	Depression in Parkinson's disease. An update. <i>Advances in Neurology</i> , 2001, 86, 373-83.	0.8	37
305	Efficacy, safety, and tolerability of overnight switching from immediate-release pramipexole in early Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 2326-2332.	3.9	36
306	Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis. <i>Movement Disorders</i> , 2019, 34, 1041-1048.	3.9	36

#	ARTICLE	IF	CITATIONS
307	A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data. <i>Frontiers in Neurology</i> , 2021, 12, 705407.	2.4	36
308	Restless legs syndrome and motor activity during sleep in spinocerebellar ataxia type 6. <i>Sleep Medicine</i> , 2006, 7, 529-532.	1.6	35
309	Fragmentary myoclonus in sleep revisited: A polysomnographic study in 62 patients. <i>Sleep Medicine</i> , 2011, 12, 410-415.	1.6	35
310	Towards translational therapies for multiple system atrophy. <i>Progress in Neurobiology</i> , 2014, 118, 19-35.	5.7	35
311	Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 156-160.	1.5	35
312	Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. <i>Movement Disorders</i> , 2016, 31, 1649-1657.	3.9	35
313	Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial. <i>Brain Stimulation</i> , 2018, 11, 1368-1377.	1.6	35
314	Dopamine D2 receptor imaging with iodine-123-iodobenzamide SPECT in idiopathic rotational torticollis. <i>Journal of Nuclear Medicine</i> , 1994, 35, 1921-7.	5.0	35
315	Visuoperception and visuospatial and visuorotational performance in Parkinson's disease. <i>Journal of Neurology</i> , 1987, 235, 99-101.	3.6	34
316	No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy). <i>Neuroscience</i> , 2001, 102, 581-592.	2.3	34
317	Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). <i>Journal of Neural Transmission</i> , 2005, 112, 1025-1033.	2.8	34
318	Depression in Parkinson's disease. <i>Journal of Neurology</i> , 2007, 254, 49-55.	3.6	34
319	Effects of Erythropoietin on Frataxin Levels and Mitochondrial Function in Friedreich Ataxia â€” a Dose-Response Trial. <i>Cerebellum</i> , 2011, 10, 763-769.	2.5	34
320	A Prospective Video-Polysomnographic Analysis of Movements during Physiological Sleep in 100 Healthy Sleepers. <i>Sleep</i> , 2015, 38, 1479-1487.	1.1	34
321	Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease. <i>Neurologic Clinics</i> , 2020, 38, 255-267.	1.8	34
322	Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. <i>Movement Disorders</i> , 2011, 26, 1935-1938.	3.9	33
323	Cerebral autoregulation and white matter lesions in Parkinson's disease and multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1393-1397.	2.2	33
324	Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 177-186.	2.8	33

#	ARTICLE	IF	CITATIONS
325	Parkinson's disease and arithmetics: The role of executive functions. <i>Journal of the Neurological Sciences</i> , 2006, 248, 124-130.	0.6	32
326	Placebo-controlled trial of riluzole in multiple system atrophy. <i>European Journal of Neurology</i> , 2006, 13, 1146-1148.	3.3	32
327	Tesofensine (NS 2330), a Monoamine Reuptake Inhibitor, in Patients With Advanced Parkinson Disease and Motor Fluctuations. <i>Archives of Neurology</i> , 2008, 65, 577.	4.5	32
328	Is transcranial sonography useful to distinguish scans without evidence of dopaminergic deficit patients from Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 1182-1185.	3.9	32
329	Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2015, 30, 976-981.	3.9	32
330	The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. <i>Journal of Neural Transmission</i> , 2016, 123, 439-445.	2.8	32
331	The neuropsychiatric phenotype in <i>CACNA1A</i> mutations: a retrospective single center study and review of the literature. <i>European Journal of Neurology</i> , 2019, 26, 66.	3.3	32
332	Validation of a mail questionnaire for parkinsonism in two languages (German and Italian). <i>Journal of Neurology</i> , 1999, 246, 79-86.	3.6	31
333	The scale for the assessment and rating of ataxia correlates with dysarthria assessment in Friedreich's ataxia. <i>Journal of Neurology</i> , 2012, 259, 420-426.	3.6	31
334	Quantitative assessment of isolated rapid eye movement (REM) sleep without atonia without clinical REM sleep behavior disorder: clinical and research implications. <i>Sleep Medicine</i> , 2014, 15, 1009-1015.	1.6	31
335	Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease. <i>European Journal of Neurology</i> , 2014, 21, 736-743.	3.3	31
336	Region-Specific Effects of Immunotherapy With Antibodies Targeting α -synuclein in a Transgenic Model of Synucleinopathy. <i>Frontiers in Neuroscience</i> , 2018, 12, 452.	2.8	31
337	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 750-762.	1.5	31
338	Cognition in multiple system atrophy: a single-center cohort study. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 219-228.	3.7	31
339	Clinical studies with transdermal rotigotine in early Parkinson's disease. <i>Neurology</i> , 2005, 65, S11-4.	1.1	31
340	Mode of vagus nerve stimulation differentially affects sleep related breathing in patients with epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2009, 18, 339-342.	2.0	30
341	A Descriptive Analysis of Neck Myoclonus During Routine Polysomnography. <i>Sleep</i> , 2010, 33, 1091-1096.	1.1	30
342	Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa-Undertreated Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2012, 35, 174-181.	0.7	30

#	ARTICLE	IF	CITATIONS
343	Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety. <i>Journal of Parkinson's Disease</i> , 2019, 9, 531-541.	2.8	30
344	Distal myasthenia gravis - frequency and clinical course in a large prospective series. <i>Acta Neurologica Scandinavica</i> , 2003, 108, 209-211.	2.1	29
345	Social stigmatization in patients with cranial and cervical dystonia. <i>Movement Disorders</i> , 2006, 21, 1636-1640.	3.9	29
346	Auditory Startle Reaction is disinhibited in idiopathic Restless Legs Syndrome. <i>Sleep</i> , 2007, 30, 489-493.	1.1	29
347	Motor disturbances during non-REM and REM sleep in narcolepsy-cataplexy: a video-polysomnographic analysis. <i>Journal of Sleep Research</i> , 2011, 20, 514-521.	3.2	29
348	Natural course of restless legs syndrome/Willisâ€™Ekbom disease: long-term observation of a large clinical cohort. <i>Sleep Medicine</i> , 2015, 16, 1252-1258.	1.6	29
349	Gray matter abnormalities of the dorsal posterior cingulate in sleep walking. <i>Sleep Medicine</i> , 2017, 36, 152-155.	1.6	29
350	Multimodal Magnetic Resonance Imaging reveals alterations of sensorimotor circuits in restless legs syndrome. <i>Sleep</i> , 2019, 42, .	1.1	29
351	Safety and Tolerability of Active Immunotherapy Targeting Î±-Synuclein with PD03A in Patients with Early Parkinsonâ€™s Disease: A Randomized, Placebo-Controlled, Phase 1 Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1079-1089.	2.8	29
352	The premorbid personality of patients with Parkinson's disease: a comparative study with healthy controls and patients with essential tremor. <i>Advances in Neurology</i> , 1990, 53, 339-42.	0.8	29
353	Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. <i>Advances in Neurology</i> , 1993, 60, 656-9.	0.8	29
354	How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?. <i>Movement Disorders</i> , 2022, 37, 1581-1592.	3.9	29
355	Riluzole therapy in cervical dystonia. <i>Movement Disorders</i> , 2002, 17, 198-200.	3.9	28
356	Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. <i>Journal of Neuroscience Research</i> , 2004, 78, 87-91.	2.9	28
357	Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy). <i>Neurobiology of Disease</i> , 2004, 15, 630-639.	4.4	28
358	Substantia Nigra Hyperechogenicity as a Marker for Parkinson's Disease: A Population-Based Study. <i>Neurodegenerative Diseases</i> , 2013, 12, 212-218.	1.4	28
359	No association of GBA mutations and multiple system atrophy. <i>European Journal of Neurology</i> , 2013, 20, e61-2.	3.3	28
360	A Prospective Questionnaire Study in 100 Healthy Sleepers: Non-Bothersome Forms of Recognizable Sleep Disorders Are Still Present. <i>Journal of Clinical Sleep Medicine</i> , 2014, 10, 623-629.	2.6	28

#	ARTICLE	IF	CITATIONS
361	New insights into atypical parkinsonism. <i>Current Opinion in Neurology</i> , 2011, 24, 331-338.	3.6	27
362	Predictors for mild parkinsonian signs: A prospective population-based study. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 321-324.	2.2	27
363	Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2018, 49, 81-87.	2.2	27
364	The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. <i>Clinical Neuropharmacology</i> , 1998, 21, 169-75.	0.7	27
365	Changes in the miRNA-mRNA Regulatory Network Precede Motor Symptoms in a Mouse Model of Multiple System Atrophy: Clinical Implications. <i>PLoS ONE</i> , 2016, 11, e0150705.	2.5	26
366	Optimal deep brain stimulation sites and networks for cervical vs. generalized dystonia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2114985119.	7.1	26
367	The ?risus sardonicus? of multiple system atrophy. <i>Movement Disorders</i> , 2003, 18, 1211-1211.	3.9	25
368	The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent Î±-synuclein in experimental multiple system atrophy. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 165513.	3.8	25
369	Safety Profile of Opicapone in the Management of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 733-740.	2.8	25
370	Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease. <i>Neurology</i> , 2020, 95, e2854-e2865.	1.1	25
371	New hopes for disease modification in Parkinson's Disease. <i>Neuropharmacology</i> , 2020, 171, 108085.	4.1	25
372	Tardive jaw tremor. <i>Movement Disorders</i> , 1997, 12, 460-462.	3.9	24
373	Evaluation of [123I]IBZM pinhole SPECT for the detection of striatal dopamine D2 receptor availability in rats. <i>NeuroImage</i> , 2005, 24, 822-831.	4.2	24
374	Cognitive outcome of pallidal deep brain stimulation for primary cervical dystonia: One year follow up results of a prospective multicenter trial. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 976-980.	2.2	24
375	Functional connectivity and topology in patients with restless legs syndrome: a case-control resting-state functional magnetic resonance imaging study. <i>European Journal of Neurology</i> , 2021, 28, 448-458.	3.3	24
376	APOMORPHINE TEST FOR DOPAMINERGIC RESPONSIVENESS. <i>Lancet, The</i> , 1989, 333, 1262-1263.	18.7	23
377	Reversible severe myopathy of respiratory muscles due to adult-onset type III glycogenosis. <i>Neuromuscular Disorders</i> , 1999, 9, 408-410.	0.6	23
378	Striatal transplantation in a rodent model of multiple system atrophy: Effects on L-Dopa response. <i>Journal of Neuroscience Research</i> , 2009, 87, 1679-1685.	2.9	23

#	ARTICLE	IF	CITATIONS
379	Apomorphine and levodopa in Parkinson's disease: Two revolutionary drugs from the 1950's. <i>Parkinsonism and Related Disorders</i> , 2016, 33, S9-S12.	2.2	23
380	Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 60-65.	2.2	23
381	Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel. <i>European Journal of Neurology</i> , 2019, 26, 581.	3.3	23
382	Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based study. <i>Parkinsonism and Related Disorders</i> , 2020, 70, 51-54.	2.2	23
383	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1816-1830.	3.7	23
384	Pharmacological Study in Meige's Syndrome with Predominant Blepharospasm. <i>Clinical Neuropharmacology</i> , 1988, 11, 68-76.	0.7	22
385	An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes. <i>Proteome Science</i> , 2012, 10, 71.	1.7	22
386	Orthostatic Hypotension Is Differentially Associated with the Cerebellar Versus the Parkinsonian Variant of Multiple System Atrophy: a Comparative Study. <i>Cerebellum</i> , 2012, 11, 223-226.	2.5	22
387	Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 50-56.	3.3	22
388	Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS. <i>Movement Disorders</i> , 2015, 30, 589-592.	3.9	22
389	Asian perspectives on the recognition and management of levodopa "wearing-off" in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 1285-1297.	2.8	22
390	Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. <i>Clinical Autonomic Research</i> , 2021, 31, 157-164.	2.5	22
391	Bioenergetics of the Calf Muscle in Friedreich Ataxia Patients Measured by 31P-MRS Before and After Treatment with Recombinant Human Erythropoietin. <i>PLoS ONE</i> , 2013, 8, e69229.	2.5	22
392	Perseverative motor behaviour in Parkinson's disease. <i>Neuropsychologia</i> , 1994, 32, 799-804.	1.6	21
393	Daytime sleepiness is not increased in mild to moderate multiple sclerosis: a pupillographic study. <i>Sleep Medicine</i> , 2005, 6, 543-547.	1.6	21
394	Early distinction of Parkinson-variant multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 440-441.	3.9	21
395	Premorbid personality of Parkinson patients. <i>Journal of Neural Transmission Supplementum</i> , 1983, 19, 215-24.	0.5	21
396	Daytime sleepiness and the COMT val158met polymorphism in patients with Parkinson disease. <i>Sleep</i> , 2006, 29, 108-11.	1.1	21

#	ARTICLE	IF	CITATIONS
397	Prodromal Parkinson's disease: hype or hope for disease-modification trials?. Translational Neurodegeneration, 2022, 11, 11.	8.0	21
398	Fourth meeting of the European Neurological Society 25â€“29 June 1994 Barcelona, Spain. Journal of Neurology, 1994, 241, 1-164.	3.6	20
399	Intact Olfaction in a Mouse Model of Multiple System Atrophy. PLoS ONE, 2013, 8, e64625.	2.5	20
400	Consistency of â€œProbable <sc>RBD</sc>â€•Diagnosis with the <sc>RBD</sc> Screening Questionnaire: A Followâ€“up Study. Movement Disorders Clinical Practice, 2017, 4, 403-405.	1.5	20
401	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1 <sc>â€•Year</sc> Data from the <sc>Openâ€“Label BeyoND</sc> Study. Movement Disorders, 2021, 36, 2687-2692.	3.9	20
402	Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): Placebo-controlled, polysomnographic case report. Movement Disorders, 2001, 16, 1177-1179.	3.9	19
403	Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinsonâ€™s disease patients with wearing-off. Journal of Neural Transmission, 2015, 122, 1709-1714.	2.8	19
404	<i>Banisteriopsis caapi</i>, a Forgotten Potential Therapy for Parkinson's Disease?. Movement Disorders Clinical Practice, 2016, 3, 19-26.	1.5	19
405	Urinary retention discriminates multiple system atrophy from Parkinson's disease. Movement Disorders, 2019, 34, 1926-1928.	3.9	19
406	Levodopaâ€“carbidopa intestinal gel in a subgroup of patients with dyskinesia at baseline from the GLORIA Registry. Neurodegenerative Disease Management, 2019, 9, 39-46.	2.2	19
407	Identification of Restless Legs Syndrome Genes by Mutational Load Analysis. Annals of Neurology, 2020, 87, 184-193.	5.3	19
408	The Unified Multiple System Atrophy Rating Scale: Intrarater reliability. Movement Disorders, 2012, 27, 1683-1685.	3.9	18
409	Taking sides: Is handedness involved in motor asymmetry of Parkinson's disease?. Movement Disorders, 2012, 27, 171-173.	3.9	18
410	Adenosine A2A receptor antagonists in Parkinson's disease: still in the running. Lancet Neurology, The, 2014, 13, 748-749.	10.2	18
411	Multiple system atrophy as emerging template for accelerated drug discovery in α -synucleinopathies. Parkinsonism and Related Disorders, 2014, 20, 793-799.	2.2	18
412	IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. Parkinsonism and Related Disorders, 2017, 38, 102-103.	2.2	18
413	Clinical Rating Scales for Urinary Symptoms in Parkinson Disease: Critique and Recommendations. Movement Disorders Clinical Practice, 2018, 5, 479-491.	1.5	18
414	Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. Parkinsonism and Related Disorders, 2020, 77, 57-63.	2.2	18

#	ARTICLE	IF	CITATIONS
415	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]-PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129.	3.9	18
416	Characterization of gait variability in multiple system atrophy and Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 1770-1779.	3.6	18
417	Cortical evoked potentials of the vesicourethral junction - a predictor for the outcome of intravesical electrostimulation in patients with sensory and motor detrusor dysfunction. <i>World Journal of Urology</i> , 1998, 16, 308-312.	2.2	17
418	Apoptosis signals in sporadic amyotrophic lateral sclerosis: an immunocytochemical study. <i>Acta Neuropathologica</i> , 2001, 102, 426-434.	7.7	17
419	Postural hand tremor before and following liver transplantation and immunosuppression with cyclosporine or tacrolimus in patients without clinical signs of hepatic encephalopathy. <i>Clinical Transplantation</i> , 2004, 18, 429-433.	1.6	17
420	Erythropoietin is neuroprotective in a transgenic mouse model of multiple system atrophy. <i>Movement Disorders</i> , 2011, 26, 507-515.	3.9	17
421	Drug safety evaluation of rotigotine. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 503-512.	2.4	17
422	Is transcranial sonography useful to distinguish drug-induced parkinsonism from Parkinson's disease?. <i>Movement Disorders</i> , 2012, 27, 1194-1196.	3.9	17
423	A follow-up study of substantia nigra echogenicity in healthy adults. <i>Movement Disorders</i> , 2012, 27, 1196-1197.	3.9	17
424	Therapeutic advances in multiple system atrophy and progressive supranuclear palsy. <i>Movement Disorders</i> , 2015, 30, 1528-1538.	3.9	17
425	Involvement of Peripheral Nerves in the Transgenic PLP- α -Syn Model of Multiple System Atrophy: Extending the Phenotype. <i>PLoS ONE</i> , 2015, 10, e0136575.	2.5	17
426	Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor. <i>Movement Disorders</i> , 2016, 31, 579-583.	3.9	17
427	Neuroprotection by Epigenetic Modulation in a Transgenic Model of Multiple System Atrophy. <i>Neurotherapeutics</i> , 2016, 13, 871-879.	4.4	17
428	Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 33-40.	2.2	17
429	The role of insulin in age-related sex differences of cardiovascular risk profile and morbidity. <i>Atherosclerosis</i> , 1997, 130, 183-189.	0.8	16
430	Cortical and brain stem hyperexcitability in striatonigral degeneration. <i>Movement Disorders</i> , 1998, 13, 602-607.	3.9	16
431	Progressive multifocal leukoencephalopathy presenting with an isolated focal movement disorder. <i>Movement Disorders</i> , 2000, 15, 1006-1009.	3.9	16
432	Linguistic and neuropsychological deficits in crossed conduction aphasia. Report of three cases. <i>Brain and Language</i> , 2004, 88, 83-95.	1.6	16

#	ARTICLE	IF	CITATIONS
433	Subjective Visual Vertical in PD Patients with Lateral Trunk Flexion. <i>Parkinson's Disease</i> , 2016, 2016, 1-4.	1.1	16
434	Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 23-27.	2.2	16
435	Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). <i>Journal of Neural Transmission</i> , 2019, 126, 1061-1072.	2.8	16
436	Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 87-91.	2.2	16
437	Rapid eye movement sleep behavior disorder and rapid eye movement sleep without atonia are more frequent in advanced versus early Parkinson's disease. <i>Sleep</i> , 2021, 44, .	1.1	16
438	On-Demand Therapy for OFF Episodes in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2244-2253.	3.9	16
439	Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. <i>Advances in Neurology</i> , 1999, 80, 545-8.	0.8	16
440	Nonmotor symptoms in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 581-583.	2.8	15
441	Measurement of costs and scales for outcome evaluation in health economic studies of Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 169-176.	3.9	15
442	Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. <i>Journal of Parkinson's Disease</i> , 2019, 9, 681-691.	2.8	15
443	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	2.2	15
444	Deep brain stimulation reduces (nocturnal) dyskinetic exacerbations in patients with ADCY5 mutation: a case series. <i>Journal of Neurology</i> , 2020, 267, 3624-3631.	3.6	15
445	Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 241-245.	3.9	15
446	Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD). <i>PLoS ONE</i> , 2015, 10, e0145493.	2.5	14
447	Minimally clinically important decline in the parkinsonian variant of multiple system atrophy. <i>Movement Disorders</i> , 2016, 31, 1577-1581.	3.9	14
448	Autonomic function testing in Friedreich's ataxia. <i>Journal of Neurology</i> , 2018, 265, 2015-2022.	3.6	14
449	Haste makes waste: Decision making in patients with restless legs syndrome with and without augmentation. <i>PLoS ONE</i> , 2017, 12, e0174793.	2.5	14
450	Akathisia induced by necrosis of the basal ganglia after carbon monoxide intoxication. <i>Movement Disorders</i> , 1995, 10, 229-231.	3.9	13

#	ARTICLE	IF	CITATIONS
451	Restless legs syndrome in Friedreich ataxia: A polysomnographic study. <i>Movement Disorders</i> , 2011, 26, 302-306.	3.9	13
452	Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease. <i>Clinical Interventions in Aging</i> , 2012, 7, 83.	2.9	13
453	Low Bone Mineral Density in Friedreich Ataxia. <i>Cerebellum</i> , 2014, 13, 549-557.	2.5	13
454	Movement Disorders in Systemic Diseases. <i>Neurologic Clinics</i> , 2015, 33, 269-297.	1.8	13
455	Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage. <i>Journal of Parkinson's Disease</i> , 2016, 6, 741-749.	2.8	13
456	Pharmacogenetics of Parkinson's Disease in Clinical Practice. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 173-180.	1.5	13
457	Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2018, 8, 161-170.	2.2	13
458	Autonomic function testing in spinocerebellar ataxia type 2. <i>Clinical Autonomic Research</i> , 2018, 28, 341-346.	2.5	13
459	Lack of Asymmetry of Nigrostriatal Dopaminergic Function in Healthy Subjects. <i>Movement Disorders</i> , 2020, 35, 1072-1076.	3.9	13
460	Prognostic implications of the motor symptoms of Parkinson's disease with respect to clinical, computertomographic and psychometric parameters. <i>Journal of Neural Transmission</i> , 1986, 67, 1-14.	2.8	12
461	Gait analysis to assess the effects of botulinum toxin type A treatment in cerebral palsy: an open-label study in 10 children with equinus gait pattern. <i>European Journal of Neurology</i> , 1999, 6, s63-s67.	3.3	12
462	In Vivo Magnetic Resonance Imaging of Embryonic Neural Grafts in a Rat Model of Striatonigral Degeneration (Multiple System Atrophy). <i>NeuroImage</i> , 2000, 12, 209-218.	4.2	12
463	Prognostic Value of Intraventricular Blood in Perimesencephalic Nonaneurysmal Subarachnoid Hemorrhage. <i>Journal of Computer Assisted Tomography</i> , 2001, 25, 742-746.	0.9	12
464	Treatment of the nonmotor symptoms of Parkinson disease. <i>Nature Reviews Neurology</i> , 2010, 6, 417-418.	10.1	12
465	Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 180-187.	3.3	12
466	Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy. <i>Brain Research Bulletin</i> , 2005, 68, 54-58.	3.0	11
467	Periodic limb movement counting in polysomnography: Effects of amplitude. <i>Sleep Medicine</i> , 2006, 7, 249-254.	1.6	11
468	Is there a polysomnographic signature of augmentation in restless legs syndrome?. <i>Sleep Medicine</i> , 2014, 15, 1231-1240.	1.6	11

#	ARTICLE	IF	CITATIONS
469	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. Expert Review of Neurotherapeutics, 2017, 17, 649-659.	2.8	11
470	Towards seeing the visual impairments in Parkinson's disease: protocol for a multicentre observational, cross-sectional study. BMC Neurology, 2019, 19, 141.	1.8	11
471	Has Deep Brain Stimulation Changed the Very Long-Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study. Movement Disorders Clinical Practice, 2020, 7, 782-787.	1.5	11
472	Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population-Based Cohort. Movement Disorders, 2020, 35, 1658-1662.	3.9	11
473	Diagnostic potential of automated tractography in progressive supranuclear palsy variants. Parkinsonism and Related Disorders, 2020, 72, 65-71.	2.2	11
474	Multimomics Analyses Identify Genes and Pathways Relevant to Essential Tremor. Movement Disorders, 2020, 35, 1153-1162.	3.9	11
475	Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study. Movement Disorders, 2021, 36, 1464-1466.	3.9	11
476	Dopamine D4 receptor polymorphism and idiopathic Parkinson's disease. European Journal of Human Genetics, 1999, 7, 397-400.	2.8	10
477	Reflection impulsivity perceptual decision-making in patients with restless legs syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 315-322.	3.7	10
478	Long duration response in Parkinson's disease: levodopa revisited. Brain, 2020, 143, 2332-2335.	7.6	10
479	Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Post-hoc Analysis of NMS Study. Movement Disorders Clinical Practice, 2022, 9, 751-758.	1.5	10
480	Failure of caspase inhibition in the double-lesion rat model of striatonigral degeneration (multiple) Tj ETQq0 0 0 rgBTJ/Overlock 10 Tf 50	7.7	9
481	Physiology of Parkinson's Disease. , 2008, , 25-36.		9
482	Intestinal levodopa infusion in PD: the first randomized trial. Nature Reviews Neurology, 2014, 10, 128-129.	10.1	9
483	Iodine-123-iodo-lisuride SPECT in Parkinson's disease. Journal of Nuclear Medicine, 1996, 37, 22-5.	5.0	9
484	Impact of Impulse Control Disorders on Sleep-Wake Regulation in Parkinson's Disease. Parkinson's Disease, 2015, 2015, 1-7.	1.1	8
485	1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism. Movement Disorders, 2016, 31, 1925-1927.	3.9	8
486	Augmentation in restless legs syndrome: an eye tracking study on emotion processing. Annals of Clinical and Translational Neurology, 2020, 7, 1620-1627.	3.7	8

#	ARTICLE	IF	CITATIONS
487	Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson's Disease Receiving a 2000mg Daily Dose of Levodopa. <i>Parkinson's Disease</i> , 2020, 2020, 1-11.	1.1	8
488	Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2021, 85, 30-36.	2.2	8
489	Dynamic balance function in phasic cervical dystonia following Botulinum toxin therapy. <i>Movement Disorders</i> , 2001, 16, 934-937.	3.9	7
490	Combined assessment of midbrain hyperechogenicity, hyposmia and motor asymmetry improves diagnostic accuracy in early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 911-914.	2.8	7
491	Plasma fasting cholesterol profiles and age at onset in Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1974-1975.	3.9	7
492	Large-scale TUBB4A mutational screening in isolated dystonia and controls. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1278-1281.	2.2	7
493	Levodopa and Parkinson Disease—Myths Revisited. <i>JAMA Neurology</i> , 2017, 74, 1270.	9.0	7
494	A Standardized MR Imaging Protocol for Parkinsonism. <i>Movement Disorders</i> , 2020, 35, 1745-1750.	3.9	7
495	Adapting to post-COVID19 research in Parkinson's disease: Lessons from a multinational experience. <i>Parkinsonism and Related Disorders</i> , 2021, 82, 146-149.	2.2	7
496	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. <i>Frontiers in Neurology</i> , 2021, 12, 754016.	2.4	7
497	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy. <i>Clinical Autonomic Research</i> , 2022, 32, 103-114.	2.5	7
498	Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology. <i>Advances in Neurology</i> , 1987, 45, 357-60.	0.8	7
499	CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1990, 53, 1105-1106.	1.9	6
500	High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence. <i>Movement Disorders</i> , 2007, 22, 969-973.	3.9	6
501	Pramipexole extended release in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1229-1234.	2.8	6
502	Axial myopathy in parkinsonism. <i>Movement Disorders</i> , 2011, 26, 1569-1571.	3.9	6
503	Movement disorders: new insights into disease mechanisms and treatment. <i>Lancet Neurology</i> , The, 2014, 13, 9-11.	10.2	6
504	Separation from Mother at Time of Weaning. <i>Tropical Doctor</i> , 1986, 16, 176-177.	0.5	5

#	ARTICLE	IF	CITATIONS
505	Is EEG useful in the differential diagnosis of parkinsonism?. Parkinsonism and Related Disorders, 1998, 4, 79-80.	2.2	5
506	Intrafamilial heterogeneity of facial hyperkinesias: Chance association of tics, cranial dystonia, and Huntington's disease?. Movement Disorders, 2001, 16, 370-372.	3.9	5
507	Can we define "pre-motor" Parkinson's disease?. Movement Disorders, 2012, 27, 595-596.	3.9	5
508	Substantia nigra hypoechogenicity in Friedreich ataxia. Movement Disorders, 2012, 27, 332-333.	3.9	5
509	Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes. Movement Disorders Clinical Practice, 2016, 3, 382-388.	1.5	5
510	Caveats of Neurodegenerative Risk Stratification in Idiopathic REM Sleep Behavior Disorder by Use of the MDS Research for Prodromal Parkinson's Disease. Sleep, 2017, 40, .	1.1	5
511	Reader response: Olfaction and incident Parkinson disease in US white and black older adults. Neurology, 2018, 90, 940-940.	1.1	5
512	Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport®). European Journal of Neurology, 2019, 26, 943.	3.3	5
513	No effect of age, gender and total intracranial volume on brainstem MR planimetric measurements. European Radiology, 2020, 30, 2802-2808.	4.5	5
514	Current strategies in the drug treatment of advanced Parkinson's disease " new modes of dopamine substitution. Acta Neurologica Scandinavica, 1993, 87, 46-49.	2.1	5
515	Dystonia—a clinical, neuropathological and therapeutic review. Journal of Neural Transmission Supplementum, 1992, 38, 91-104.	0.5	5
516	Decades of delayed diagnosis in 4 levodopa-responsive young-onset monogenetic parkinsonism patients. Movement Disorders, 2011, 26, 1337-1340.	3.9	4
517	Systematic TOR1A non-c.907_909delGAG variant analysis in isolated dystonia and controls. Parkinsonism and Related Disorders, 2016, 31, 119-123.	2.2	4
518	Insulin signalling: new target for Parkinson's treatments?. Lancet, The, 2017, 390, 1628-1630.	13.7	4
519	Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy. Movement Disorders Clinical Practice, 2017, 4, 389-396.	1.5	4
520	SOX5-Null Heterozygous Mutation in a Family with Adult-Onset Hyperkinesia and Behavioral Abnormalities. Case Reports in Genetics, 2017, 2017, 1-6.	0.2	4
521	The Frontal Assessment Battery in RLS patients with and without augmentation. Sleep Medicine, 2020, 75, 456-458.	1.6	4
522	Clinical features, diagnosis, and imaging of parkinsonian syndromes. Current Opinion in Neurology and Neurosurgery, 1993, 6, 333-8.	0.4	4

#	ARTICLE	IF	CITATIONS
523	Spasmodic torticollis - a multicentre study on behavioural aspects IV: psychopathology. Behavioural Neurology, 1996, 9, 97-103.	2.1	4
524	Eye Tracking in Patients with Parkinson's Disease Treated with Nabilone—Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study. Brain Sciences, 2022, 12, 661.	2.3	4
525	Treatment of Gait and Balance Disorders. , 2008, , 417-443.		3
526	L01—Sleep in patients with huntington's disease: an interim analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A43.3-A43.	1.9	3
527	Diagnosis of drug-induced parkinsonism: can transcranial sonography make the difference?. European Journal of Neurology, 2013, 20, 1429-1430.	3.3	3
528	On —Polysomnography reveals unexpectedly high rates of organic sleep disorders in patients with prediagnosed primary insomnia—(Sleep Breath 2011 doi 10.1007/s11325-011-0608-8). Sleep and Breathing, 2013, 17, 1-2.	1.7	3
529	Perimenstrual Fluctuations in Two Siblings With Early-Onset Parkinson's Disease. Movement Disorders Clinical Practice, 2014, 1, 125-127.	1.5	3
530	Rifampicin for multiple system atrophy. Lancet Neurology, The, 2014, 13, 237-239.	10.2	3
531	Vertical supranuclear gaze palsy induced by deep brain stimulation: Report of two cases. Parkinsonism and Related Disorders, 2014, 20, 1295-1297.	2.2	3
532	Influence of a Post-Test Factor on the Results of the Multiple Sleep Latency Test. Journal of Clinical Sleep Medicine, 2016, 12, 529-531.	2.6	3
533	The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease. Clinical Neuropharmacology, 2016, 39, 88-93.	0.7	3
534	Imaging markers of disease progression in multiple system atrophy. Future Neurology, 2019, 14, FNL24.	0.5	3
535	Neurological research & training after the easing of lockdown in countries impacted by COVID-19. Journal of the Neurological Sciences, 2020, 418, 117105.	0.6	3
536	Predictors of Response for —Off—Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry. Frontiers in Neurology, 2020, 11, 419.	2.4	3
537	Experience with selegiline in the treatment of Parkinson's disease. Journal of Neural Transmission Supplementum, 1987, 25, 131-5.	0.5	3
538	Use of botulinum toxin in the treatment of cervical dystonia. Baillière's Clinical Neurology, 1993, 2, 179-85.	0.2	3
539	How to run a "brain bank"? Clinical and institutional requirements for "brain banking". Journal of Neural Transmission Supplementum, 1993, 39, 71-5.	0.5	3
540	IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls. Advances in Neurology, 1993, 60, 525-8.	0.8	3

#	ARTICLE	IF	CITATIONS
541	Associations of Gait Disorders and Recurrent Falls in Older People: A Prospective Population-Based Study. <i>Gerontology</i> , 2022, 68, 1139-1144.	2.8	3
542	Spasmodic torticollis - a multicentre study on behavioural aspects II: signs, symptoms and course. <i>Behavioural Neurology</i> , 1996, 9, 81-8.	2.1	3
543	Spasmodic torticollis - a multicentre study on behavioural aspects III: psychosocial changes and coping. <i>Behavioural Neurology</i> , 1996, 9, 89-95.	2.1	3
544	Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991, 54, 186-187.	1.9	2
545	General Management Approach to Dystonia. , 2008, , 217-226.		2
546	Managing the Non-Motor Symptoms of Parkinson's Disease. , 2008, , 91-120.		2
547	Surgery for Parkinson's Disease. , 2008, , 121-143.		2
548	Myoclonus. , 2008, , 363-370.		2
549	Austria. <i>Practical Neurology</i> , 2009, 9, 298-301.	1.1	2
550	P2.152 Changes in early-morning motor status following adjunctive treatment of advanced Parkinson's disease with rotigotine transdermal system: two large, placebo-controlled trials. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S130-S131.	2.2	2
551	Defining premotor Parkinsonâ€™s disease: a window of opportunity for neuroprotection?. <i>Neurodegenerative Disease Management</i> , 2013, 3, 61-70.	2.2	2
552	Multiple system atrophyâ€™ new insight from prospective studies. <i>Nature Reviews Neurology</i> , 2015, 11, 430-431.	10.1	2
553	The role of exposure to pesticides in the etiology of Parkinsonâ€™s disease: a 18F-DOPA positron emission tomography study. <i>Journal of Neural Transmission</i> , 2019, 126, 159-166.	2.8	2
554	Impaired Inhibitory Control of Saccadic Eye Movements in Cervical Dystonia: An Eyeâ€™Tracking Study. <i>Movement Disorders</i> , 2021, 36, 1246-1250.	3.9	2
555	Recent advances in the drug treatment of Parkinsonâ€™s disease. <i>Current Opinion in Neurology</i> , 1999, 12, 411-415.	3.6	2
556	Myotonic myopathy with painful muscle contractions and decrease of symptoms by cold. <i>Journal of Neurology</i> , 1978, 219, 133-137.	3.6	1
557	Disturbance of time perception in left hemispheric migraine aura. <i>Journal of Neurology</i> , 1996, 243, 611-611.	3.6	1
558	Evoked potentials in a case of progressive multifocal leukoencephalopathy. <i>Journal of Neurology</i> , 2003, 250, 236-238.	3.6	1

#	ARTICLE	IF	CITATIONS
559	Botulinum Toxin for Treatment of Dystonia. , 2008, , 227-240.		1
560	Chorea. , 2008, , 317-330.		1
561	Essential Tremor. , 2008, , 177-191.		1
562	Pathophysiology of Dystonia. , 2008, , 203-215.		1
563	Pharmacology of Parkinson's Disease. , 2008, , 37-48.		1
564	The Treatment of Early Parkinson's Disease. , 2008, , 49-70.		1
565	Parkinson-Plus Disorders. , 2008, , 157-175.		1
566	Invasive Treatment Strategies in a Patient with <scp>PARK</scp> 15â€™Associated Parkinsonism. Movement Disorders Clinical Practice, 2015, 2, 434-435.	1.5	1
567	Reply: Nonmotor symptoms in subjects without evidence of dopaminergic deficits. Movement Disorders, 2015, 30, 1437-1438.	3.9	1
568	Utility of Nigral Signal Intensity Changes on MR Images to Differentiate Drug-induced Parkinsonism from Parkinson Disease. Radiology, 2016, 281, 651-652.	7.3	1
569	Long-term efficacy of inhaled levodopa in Parkinsonâ€™s disease subjects with motor fluctuations: Interim results of a phase 3 study. Parkinsonism and Related Disorders, 2018, 46, e19.	2.2	1
570	Long-term pulmonary safety of inhaled levodopa in parkinsonâ€™s disease subjects with motor fluctuations: interim results of a phase 3 study. Parkinsonism and Related Disorders, 2018, 46, e83.	2.2	1
571	Opicapone as a levodopa sparing agent: Pooled analysis of BIPARK-I and II double-blind trials. Journal of the Neurological Sciences, 2019, 405, 218-219.	0.6	1
572	Opicapone odds ratio in relative off-time reduction: A post-hoc analysis from combined BIPARK-I and II data. Journal of the Neurological Sciences, 2019, 405, 87-88.	0.6	1
573	Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?. Movement Disorders, 2021, 36, 2703-2705.	3.9	1
574	Nighttime and morning OFF improvements with opicapone in patients with Parkinson's Disease and motor fluctuations: BIPARK-1 and BIPARK-2 pooled subanalyses. Parkinsonism and Related Disorders, 2020, 79, e53-e54.	2.2	1
575	CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease. Clinical Neuropharmacology, 1990, 13, 303-11.	0.7	1
576	Psychometric findings in clinical subtypes of Parkinson's disease. Advances in Neurology, 1987, 45, 409-11.	0.8	1

#	ARTICLE	IF	CITATIONS
577	Simple assessments of mobility. Methodology and clinical application of kinetic gait analysis. <i>Advances in Neurology</i> , 2001, 87, 101-10.	0.8	1
578	Surgical Treatments of Dystonia. , 2008, , 241-250.		0
579	Cramps and Spasms. , 2008, , 263-281.		0
580	Stiff Person Syndrome. , 2008, , 283-291.		0
581	The Etiopathogenesis of Parkinson's Disease: Basic Mechanisms of Neurodegeneration. , 2008, , 1-23.		0
582	Other Tremor Disorders. , 2008, , 193-202.		0
583	Treatment of Motor Complications in Advanced Parkinson's Disease. , 2008, , 71-90.		0
584	Future Cell- and Gene-Based Therapies for Parkinson's Disease. , 2008, , 145-156.		0
585	Huntington's Disease. , 2008, , 293-315.		0
586	Treatment of Tics and Tourette Syndrome. , 2008, , 331-344.		0
587	Therapeutics of Paroxysmal Dyskinesias. , 2008, , 345-352.		0
588	Treatment of Miscellaneous Disorders. , 2008, , 353-362.		0
589	Neuroleptic-Induced Movement Disorders. , 2008, , 371-387.		0
590	Other Drug-Induced Dyskinesias. , 2008, , 389-403.		0
591	Ataxia. , 2008, , 405-415.		0
592	The Restless Legs Syndrome. , 2008, , 445-467.		0
593	Pediatric Movement Disorders. , 2008, , 469-476.		0
594	Psychogenic Movement Disorders. , 2008, , 477-488.		0

#	ARTICLE	IF	CITATIONS
595	P1.11 Dysautonomia Rating Scales in Parkinson's disease: Symptoms of orthostatic hypotension. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2009, 149, 63.	2.8	0
596	Reply: "Restless Legs Syndrome and Parkinson's Disease". <i>Movement Disorders</i> , 2010, 25, 1314-1315.	3.9	0
597	Risk of dyskinesia in Parkinson's disease patients who already have developed wearing-off: A secondary analysis of STRIDE-PD study. <i>Journal of the Neurological Sciences</i> , 2013, 333, e65-e66.	0.6	0
598	I15 Sleep In Patients With Huntington's Disease: Interim Results From A Polysomnographic Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, A63-A63.	1.9	0
599	Poster 155 Dysport® (AbobotulinumtoxinA) is Effective with a Favorable Safety Profile in the Treatment of Cervical Dystonia: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study. <i>PM and R</i> , 2014, 6, S238-S239.	1.6	0
600	Poster 156 Dysport® (AbobotulinumtoxinA) Improves Disease-Specific Quality of Life in Patients with Cervical Dystonia, as Measured by Patient-Reported Outcomes, in a Phase III, Randomized, Double-Blind, Placebo-Controlled Study. <i>PM and R</i> , 2014, 6, S239.	1.6	0
601	Preface. <i>Movement Disorders</i> , 2015, 30, 1441-1441.	3.9	0
602	Eldad Melamed 1942-2015: Ave atque-A memorial. <i>Movement Disorders</i> , 2016, 31, 39-40.	3.9	0
603	Reply to letter: Nonmotor symptoms in subjects without evidence of dopaminergic deficits. <i>Movement Disorders</i> , 2016, 31, 1588-1589.	3.9	0
604	Reply to "Nonmotor symptoms in subjects without evidence of dopaminergic deficit" authors: "Swallow DMA, Grosset KA, Grosset DG". <i>Movement Disorders</i> , 2016, 31, 430-431.	3.9	0
605	Levodopa-carbidopa intestinal gel treatment in patients with < 10 years of Parkinson's disease: GLORIA registry interim results. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e93-e94.	2.2	0
606	Gastrointestinal safety of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients: GLORIA long-term registry interim results. <i>Parkinsonism and Related Disorders</i> , 2016, 22, e96-e97.	2.2	0
607	Response to: On the role of visual electrophysiology in parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 45, 98.	2.2	0
608	Franz Gerstenbrand - Obituary. <i>European Journal of Neurology</i> , 2017, 24, 1089-1090.	3.3	0
609	0673 Multimodal MRI Reveals Alterations Of Sensorimotor Circuits In Restless Legs Syndrome. <i>Sleep</i> , 2019, 42, A268-A270.	1.1	0
610	Smelling Parkinson's Disease: New Metabolomic Biomarker for PD. <i>ACS Central Science</i> , 2019, 5, 575-576.	11.3	0
611	Effect of opicapone in Parkinson's disease patients with "early" motor fluctuations: Parkinson's disease questionnaire (PDQ-39) analysis from the BIPARK-I double-blind experience. <i>Journal of the Neurological Sciences</i> , 2019, 405, 190-191.	0.6	0
612	Efficacy of opicapone in Parkinson's disease patients with "early" motor fluctuations: Patient and clinical global impression of change from the BIPARK-I double-blind experience. <i>Journal of the Neurological Sciences</i> , 2019, 405, 191-192.	0.6	0

#	ARTICLE	IF	CITATIONS
613	Incidence of treatment-emergent adverse events in Parkinson's Disease patients according to baseline body mass index: Post-hoc analysis from double-blind combined BIPARK-I and II data. <i>Journal of the Neurological Sciences</i> , 2019, 405, 200.	0.6	0
614	Efficacy of opicapone in Parkinson's disease patients according to baseline pramipexole use: A post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019, 405, 192-193.	0.6	0
615	Efficacy of opicapone in Parkinson's disease patients according to baseline rasagiline use: A post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019, 405, 193.	0.6	0
616	Oleh Hornykiewicz (1926-2020). <i>Journal of Parkinson's Disease</i> , 2020, 10, 753-756.	2.8	0
617	Efficacy of opicapone according to different levodopa daily intakes in Parkinson's disease patients with motor fluctuations. <i>Journal of the Neurological Sciences</i> , 2021, 429, 119446.	0.6	0
618	Neuropsychologische Befunde bei Stimulation der Basalganglien - ein Review. <i>Zeitschrift für Neuropsychologie = Journal of Neuropsychology</i> , 2004, 15, 287-301.	0.6	0
619	Entscheiden bei Morbus Parkinson - eine Übersicht. <i>Zeitschrift für Neuropsychologie = Journal of Neuropsychology</i> , 2008, 19, 235-251.	0.6	0
620	Efficacy of opicapone in patients with Parkinson's disease with levodopa dose reduction: a pooled post-hoc analysis of BIPARK-I and II. <i>Parkinsonism and Related Disorders</i> , 2020, 79, e62-e63.	2.2	0
621	Dopaminergic-peptidergic interactions in extrapyramidal disorders: a review of the clinical evidence. <i>Advances in Neurology</i> , 1987, 45, 67-73.	0.8	0
622	Therapeutic experiences with an aporphine derivative in Parkinson's disease. <i>Advances in Neurology</i> , 1987, 45, 591-2.	0.8	0
623	Lack of selective vulnerability to anticholinergic induced cognitive impairment in early Parkinson's disease. <i>Behavioural Neurology</i> , 1991, 4, 103-11.	2.1	0